The Latest Breaking News from Pfizer

COVID-19 vaccines tweaked to better match today’s omicron threat are expected to roll out in a few weeks but how much will they help

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

Cerevel Therapeutics more than doubled its cash balance to keep pace with Karuna Therapeutics in a head-to-head showdown.

LOS ANGELES — California schools reopened for the fall semester with loosened COVID-19 protocols and low student vaccination rates among younger children, presenting a new test for the trajectory of the pandemic as some experts expect another rise in cases when winter arrives.

Moderna stock inched higher late Tuesday just before announcing it asked the FDA to sign off on its updated Covid booster shot.

Pfizer’s says its COVID-19 vaccine was 73% effective in protecting children younger than 5 as omicron spread in the spring

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 10 strange trades.

Pfizer Inc.’s COVID-19 vaccine was 73.2% effective against the disease in a trial of children 6 months through 4 years old, reinforcing results that led to the shot’s authorization in young kids in June.

Pfizer Inc. and BioNTech SE asked the U.S. to authorize a new COVID-19 booster shot customized against the currently circulating COVID-19 variants as governments race to protect their populations against the ever-mutating virus.